New drug access opens for severe, untreatable hives
NCT ID NCT05170724
Summary
This program provides access to the investigational drug remibrutinib for adults with severe chronic spontaneous urticaria (CSU), also known as chronic hives. It is for patients whose hives have lasted over 6 months and have not responded to standard antihistamine treatments or other approved therapies. The goal is to control the disease and reduce symptoms for patients who have no other treatment options available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.